Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:20 PM
Ignite Modification Date:
2025-12-24 @ 1:20 PM
NCT ID:
NCT04808895
Eligibility Criteria:
Inclusion Criteria:
* in a medical area ward dedicated to Covid-19 patients
* Positivity by RT\_PCR of the search for genetic material of SARS-CoV2
* Covid-19 pneumonia with moderate clinical picture based on clinical parameters
* O2 saturation\> 94% with maximum FiO2 32%
* Respiratory acts \<30 / minute
* age \>18 years
* Consent to participate in the study
Exclusion Criteria:
* Any Antithrombotic treatment including acetylsalicylic acid
* Active Bacterial infection
* Active or in maintenance therapy neoplasm
* Inability to provide consent
* Any contraindication to the acetylsalicylic acid use
* Active peptic disease
* Active Major pathological bleeding
* Recent (\<30 days) major bleeding
* Recent intracranial bleeding
* Need to use therapeutic doses of oral anticoagulants or heparins
* Need to use combination antiplatelet drugs for clinical indication
* Hypersensitivity to acetylsalicylic acid or to any of the excipients
* Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs)
* Severe hepatic insufficiency (Child-Pugh class C).
* Severe heart failure (NYHA class 3-4)
* Platelet count less than 150000 / mmc
* Haemostasis alteration (INR\> 1.5, APTT\> 1.5)
* Plasma fibrinogen \<100 mg / dL
* Blood pressure \>160/100 mmHg
* Concomitant treatment with serotonin reuptake inhibitors
* Participation in another pharmacological clinical trial
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
99 Years
Study:
NCT04808895
Study Brief:
Protocol Section:
NCT04808895